SOURCE: Crucell N.V.

January 31, 2007 02:10 ET

Crucell announces STAR™ Research License Agreement

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- January 31, 2007 --



Leiden, The Netherlands, January 31, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a non-exclusive STAR™ research license agreement for the production of monoclonal antibodies with Abbott Park, Illinois-based Abbott. Under the agreement, Abbott would evaluate Crucell's STAR™ technology for generating cell lines for manufacture of biopharmaceuticals. Financial details were not disclosed.

For further information please contact:


Crucell N.V.
Leonard Kruimer
Chief Financial Officer Barbara Mulder
Tel. +31-(0)71-524 8722 Tel: 31-(0) 71 524 8718
l.kruimer@crucell.com   barbara.mulder@crucell.com




Copyright © Hugin ASA 2007. All rights reserved.

Contact Information